Aidea Pharmaceutical released its 2026 interim report, with total operating revenue of 366 million yuan and net profit attributable to the parent company of 22.93 million yuan. The company's net cash inflow from operating activities was 25.06 million yuan, its asset-liability ratio was 50.67%, gross margin was 65.49%, return on equity was 2.51%, and diluted earnings per share was 0.05 yuan. The number of shareholders was 12,200, and the top ten shareholders held 58.66% of the total share capital.
Jiangsu Aidea Pharmaceutical Co LtdCompany reports net profit of 22.93 million yuan for 2026 interim, indicating profitability.